21 results about "Blood creatinine" patented technology

The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.

The invention belongs to the technical field of reproductive medicine and clinical metabolism intervention, and particularly relates to a group of markers for diagnosing unexplained recurrent abortion and application thereof. Aiming at the clinical pain point that unexplained recurrent abortion (URSA) lacks accurate metabolic typing diagnosis indexes and targeted treatment means, based on detection of a large number of clinical samples and verification of cell experiments, direct association between down-regulation of levels of choline related metabolites and trimethylamine oxide (TMAO) of decidua tissues and the RSA is disclosed for the first time; the core effect of TMAO in-situ synthesis of decidua stromal cells (DSC) in regulation and control of the decidualization process is determined; meanwhile, an RSA indication screening system of joint detection of serum creatinine and decidua choline metabolism is constructed, a targeted TMAO targeted intervention scheme is formed in a matched mode, a diagnosis and treatment closed loop of RSA from precise typing to targeted treatment is achieved, and a brand new technical path is provided for clinically solving the URSA diagnosis and treatment problem.

The application provides a clinical rehabilitation data management and evaluation system for rhabdomyolysis patients, and relates to a medical information management system.The system comprises an index acquisition module, a rate detection module, a curvature analysis module, a node identification module and a trend construction module.In the application, the rate difference sequence of creatine kinase and myoglobin and the curvature sequence of urine sodium and blood creatinine are combined to break through the limitations of traditional single-parameter static analysis, realize dynamic capture of multi-index collaborative trend, construct a joint evolution label system by combining the consistency discrimination of creatine kinase and blood potassium concentration change direction, accurately locate the multi-system interaction risk nodes, and statistically distribute the direction consistency proportion of myoglobin and blood creatinine in the correlation period, so as to convert the discrete parameter correlation into a dynamic visual model.The method solves the problems of data dispersion misjudgment and collaborative evolution mode fragmentation in the traditional technology, and provides a multi-dimensional dynamic evaluation framework for the rhabdomyolysis rehabilitation process in clinical practice.

The present invention belongs to the technical field of diabetic nephropathy drugs, and particularly relates to a traditional Chinese medicine composition for treating early diabetic nephropathy and a preparation method thereof. The traditional Chinese medicine composition comprises the following main components by weight: 20-40 parts of astragalus, 10-20 parts of pseudoginseng, 20-40 parts of raw rehmannia, 10-20 parts of cornus officinalis, 10-20 parts of winter mallow seeds, 10-20 parts of euryale ferox, 9-15 parts of morus alba bark, 10-20 parts of zedoaria, 3-6 parts of leeches, and 3-6 parts of scorpions. The traditional Chinese medicine composition combines kidney-tonifying and spleen-invigorating drugs with blood circulation-activating and collateral-dredging drugs, and is nutritious without being greasy, and attacks pathogens without damaging the body, thereby jointly achieving the functions of invigorating the spleen and replenishing qi, tonifying the kidney, activating blood circulation and dredging collaterals, and having significant therapeutic effects in lowering blood sugar and blood creatinine, improving symptoms of diabetic nephropathy, and improving the quality of life of patients.

The invention belongs to the field of pet food processing, and relates to a premix for improving the health of urinary tracts of pets. The premix comprises the following components in parts by weight: 25-35 parts of Chinese yams, 25-35 parts of poria cocos, 15-25 parts of dandelions, 15-25 parts of centella asiatica, 15-25 parts of semen plantaginis, 5-15 parts of rhizoma polygonati, 5-15 parts of dogwood and 5-15 parts of Chinese wolfberry fruits. By adding the premix disclosed by the invention into daily ration, the concentrations of cat blood creatinine, urea nitrogen and blood oxalic acid are reduced, the absorption and excretion of oxalic acid are influenced, and the formation of calcium oxalate calculi is prevented. The premix disclosed by the invention can relieve the kidney toxicity of sodium oxalate to cats, improve the physiological indexes of the kidneys, reduce the formation of calcium oxalate calculi and provide basic guarantee for the treatment of chronic urinary system diseases. The premix disclosed by the invention can be used for improving the urinary tract health of cats.

The application discloses an application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicines.The application provides an application of the RNF130 activator in preparation of a medicine for preventing or treating kidney ischemia-reperfusion injury, and the RNF130 activator can improve kidney function of a mouse with kidney ischemia-reperfusion injury, improve levels of blood creatinine, urea nitrogen and cystatin C, reduce levels of kidney injury markers KIM-1 and LCN2, and reduce tubular injury, thereby playing a preventive and therapeutic role on kidney ischemia-reperfusion injury, and providing a new target for preparation of a medicine for preventing and treating acute kidney injury.

This invention relates to the field of biomedical technology, and more particularly to a biomarker set, staging model, and their applications for chronic kidney disease. This invention utilizes metabolomics data analysis to obtain a biomarker set based on serum creatinine. Then, through methodological optimization, a staging model for chronic kidney disease is constructed. This staging model is also used for staging chronic kidney disease, and the results are accurate, specific, precise, and highly sensitive. It eliminates the false positive problem of traditional serum creatinine-based methods and removes the influence of gender factors. Staging chronic kidney disease based on this model is more consistent with the disease's progression characteristics.

The invention discloses application of mogroside V in preparation of an anti-renal fibrosis medicine, and belongs to the technical field of biological medicines. Experiments prove that the mogroside V can obviously improve the renal function of a mouse with renal fibrosis, and the serum creatinine and blood urea nitrogen levels are obviously reduced. Meanwhile, the compound can be used for effectively inhibiting the expression of fibrosis markers alpha-SMA and Fibronectin in renal tissues, and delaying the fibrosis process by up-regulating the expression level of an epithelial-mesenchymal transition marker E-cadherin. In addition, the mogroside V can also significantly reduce collagen deposition in kidney tissues, and plays a role in treating renal fibrosis. The traditional Chinese medicine composition has the advantages of safety, effectiveness, no side effect, good taste and the like when being used for preparing the anti-renal fibrosis medicine.

The invention discloses a method for non-invasive diagnosis of serum creatinine based on Raman spectrum.The method belongs to the crossing field of analysis and detection and biomedical engineering.The method comprises the steps that firstly, a part with flat skin and rich blood vessels is selected, cleaned and dried, then the best offset with the strongest correlation between a cortex depth Raman signal and creatinine is determined through OCT scanning, and the optimal offset is obtained; the method comprises the following steps of: acquiring a spectrum through an optical fiber probe of an mmu SORS system, performing pretreatment such as baseline correction and normalization on the acquired spectrum to extract a creatinine characteristic peak, establishing a PLS regression model to correct a spectrum-concentration relationship, and finally verifying through MARD and CEG A + B region data proportion indexes. According to the method, noninvasive precise serum creatinine detection is achieved through the mmu SORS technology, the problems that in the prior art, sensitivity is low and interference is large are solved by means of Raman spectrum molecular fingerprint features and OCT depth positioning, the change trend of serum creatinine is tracked in real time through continuous detection, and dynamic monitoring and personalized medical support are provided.

The invention provides a traditional Chinese medicine composition for treating chronic renal failure as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating chronic renal failure is prepared from the following raw materials: rheum officinale, polygonum cuspidatum, leonurus, astragalus membranaceus, dandelion, poria cocos, plantain herb, herba lycopi, white mulberry root-bark, radix paeoniae alba and eclipta. The traditional Chinese medicine composition adjusts traditional Chinese medicine components, follows the compatibility principle of monarch, minister, assistant and guide and the structure theory, reasonably organizes medicines, enhances the curative effect, reduces toxic and side effects, comprehensively takes care of the illness state, improves the treatment effect of the traditional Chinese medicine composition on chronic renal failure, adjusts the abnormal levels of serum urea nitrogen and serum creatinine, and improves calcium and phosphorus metabolism disorder.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a kidney-protecting and blood stasis-removing mixture and a preparation method and application thereof. The kidney-protecting and blood stasis-eliminating mixture is composed of astragalus membranaceus, angelica sinensis, rhizoma bletillae, plantain herb, peach kernel, cooked rhubarb and scalded leech, the selected medicinal materials are appropriate in compatibility, the traditional Chinese medicine theory and the modern medicine theory are met, and the kidney-protecting and blood stasis-eliminating mixture has the effects of promoting blood circulation to remove blood stasis, tonifying kidney and spleen and eliminating dampness and heat. The kidney-protecting and blood stasis-eliminating mixture disclosed by the invention has remarkable curative effects on reducing serum creatinine, improving symptoms of chronic renal failure and acute renal failure, improving the life quality of patients and the like.

The invention discloses a pharmaceutical composition for treating chronic kidney disease stage 1-3 as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition consists of 40-60 parts of astragalus membranaceus, 40-60 parts of black soybeans, 8-12 parts of angelica sinensis, 24-36 parts of dogwood and 8-12 parts of rhodiola rosea. The preparation method comprises the following steps: pretreating the raw materials, soaking, boiling for several times and filtering to obtain a finished product. Based on the treatment principles of tonifying qi, activating blood, dredging collaterals and removing blood stasis in traditional Chinese medicine, the traditional Chinese medicine composition conforms to the pathogenesis of chronic kidney disease deficiency in root and excess in superficies, all the components synergistically play a role, the serum urea nitrogen, serum creatinine level and glomerular filtration rate of a patient can be improved and edema, weakness and other symptoms can be relieved by combining basic treatment, the total effective rate reaches 83.33%, and the traditional Chinese medicine composition is good in safety, easy and convenient to prepare and suitable for clinical application. The traditional Chinese medicine composition is suitable for long-term administration of patients with spleen and kidney qi deficiency and blood deficiency with stasis syndrome type chronic kidney diseases at 1-3 stages, and has good application value in treatment of related diseases.

The invention discloses an application of hexacosanol in preparation of a medicine for relieving and / or treating chronic kidney disease. Relates to the technical field of medicine products. It is found and proved for the first time that hexacosanol can effectively reduce serum creatinine (Scr) and urea nitrogen (BUN) levels of chronic kidney disease model animals and improve kidney pathological injuries, and shows a remarkable kidney protection effect. Besides, the invention provides a series of products containing hexacosanol, including pharmaceutical compositions for treating and / or relieving chronic kidney diseases and health products for assisting in improving and / or maintaining kidney health, and brand-new and safe natural active ingredient choices are provided for treatment and auxiliary management of chronic kidney diseases.

This invention belongs to the field of pet food processing and relates to a premix for improving the urinary tract health of pets. The premix contains the following components in parts by weight: 25-35 parts of Dioscorea opposita, 25-35 parts of Poria cocos, 15-25 parts of Taraxacum mongolicum, 15-25 parts of Centella asiatica, 15-25 parts of Plantago asiatica, 5-15 parts of Polygonatum sibiricum, 5-15 parts of Cornus officinalis, and 5-15 parts of Lycium barbarum. Adding this premix to the cat's diet reduces serum creatinine, blood urea nitrogen, and serum oxalate concentrations, affecting oxalate absorption and excretion, and preventing the formation of calcium oxalate stones. This premix can alleviate the nephrotoxicity of sodium oxalate in cats, improve renal physiological indicators, reduce the formation of calcium oxalate stones, and provide a basic guarantee for the treatment of chronic urinary system diseases. This premix can improve the urinary tract health of cats.

The invention relates to the technical field of biomedical treatment, in particular to a marker set for chronic kidney diseases, a staging model and application of the marker set and the staging model. According to the method, a marker set based on serum creatinine is obtained through metabonomics data analysis, then the staging model for staging the chronic kidney disease is constructed through methodological optimization, the staging model is used for staging the chronic liver disease, the result is accurate, specificity, precision and sensitivity are high, and the method is suitable for clinical application. The original false positive problem based on serum creatinine indexes is solved, the influence of gender factors is eliminated, and chronic kidney disease staging according to the staging model is more in line with the development characteristics of diseases.

The invention relates to a formula and a preparation method of a Shuliguguan drink for treating chronic kidney diseases from liver, and belongs to the field of traditional Chinese medicine preparations for treating chronic kidney diseases. In view of the fact that the current commercially available Chinese patent medicine for treating the CKD cannot comprehensively cover the pathogenesis of liver depression, spleen deficiency and pathogen accumulation in triple jiao, the invention provides the Chinese patent medicine which is prepared from 30g of raw astragalus membranaceus, 15g of roasted rhizoma atractylodis macrocephalae, 10g of radix bupleuri, 15g of poria cocos, 15g of cistanche, 15g of oriental wormwood, 10g of rhizoma alismatis, 15g of serissa serissoide, 15g of salvia miltiorrhiza and 10g of raw rhubarb, has the effects of strengthening body resistance, removing toxicity and dredging triple jiao, and is high in total effective rate in clinical tests for treating CKD patients with liver depression and spleen deficiency. Serum creatinine and urea nitrogen can be reduced, and urine protein excretion can be reduced; malnutrition of a patient is improved, the immune function is improved, and the kidney microinflammation state is relieved; the residual renal function is protected, and the renal fibrosis progress is delayed; compared with western medicine basic treatment, the medicine can slow down the decline rate of the glomerular filtration rate, and achieves the effects of delaying renal hypofunction and delaying dialysis starting time.

Provided is a probiotic agent comprising Akkermansia muciniphila strain Akk11 for ameliorating hypertension. Strains in the probiotic agent include Akkermansia muciniphila strain Akk11 and Lactobacillus rhamnosus strain LRa05. The two strains have potential interactions, can cooperate with each other, and work synergistically to ameliorate hypertension. Specifically, the strains significantly enhance the blood pressure regulation ability and optimize the blood pressure regulation mechanism; significantly regulate the levels of protein in urine and serum creatinine, which are renal function markers, effectively improve renal function, and alleviate kidney injuries caused by hypertension; and significantly optimize oxidative stress responses and enhance the body's defense against oxidation.

The application discloses a preparation method and application of an autologous mitochondrion preparation, relates to the technical field of kidney protection and regeneration, and is characterized in that the mitochondrion is derived from heart tissue of a healthy C57 mouse of 8-10 weeks old, is obtained through a kit combined with a differential centrifugation method, and is characterized in that the obtained mitochondrion is continuous in outer membrane and clear in ridge structure under an electron microscope, and has good structural and functional integrity. In an in-vivo experiment, the mitochondrion is delivered to the renal cortex region of a recipient mouse through a subcapsular injection method 30 minutes before ischemia-reperfusion, and the result shows that the blood creatinine and urea nitrogen levels can be significantly reduced, the necrosis and oxidative stress damage of renal tubular epithelial cells can be reduced, and the renal tissue pathological score can be improved. The application provides a repeatable and standardizable organelle treatment strategy for intervention of kidney transplantation and acute kidney injury related IRI.

The application discloses use of Bikeli tablets in preparation of a medicine for treating type II diabetic nephropathy, and belongs to the technical field of medicines. The Bikeli tablets can realize systematic treatment of type II diabetic nephropathy through systematic effects of'multi-target and multi-pathway'. The Bikeli tablets can not only control blood sugar and blood uric acid from the source, but also can effectively reduce urine protein and improve kidney function (blood creatinine and urea nitrogen), and directly act on kidney tissues to inhibit the key pathological process of kidney interstitial fibrosis which leads to permanent loss of kidney function. Therefore, the Bikeli tablets are suitable for improving clinical symptoms and functional indexes of DKD, and have long-term therapeutic value of delaying disease progression, protecting residual kidney function and preventing occurrence of end-stage renal disease.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine compound preparation for treating IgA nephropathy and a preparation method and application thereof. The traditional Chinese medicine compound preparation for treating IgA nephropathy is prepared from the following raw materials in parts by weight: angelica sinensis, roasted rhizoma atractylodis macrocephalae, radix stephaniae tetrandrae, radix saposhnikoviae, poria cocos, herba epimedii, fructus rosae laevigatae, astragalus membranaceus and curcuma zedoary. After an IgA nephropathy patient is treated by the traditional Chinese medicine compound preparation, indexes such as serum creatinine and 24-hour urine protein can be remarkably improved, and clinical symptoms are remarkably relieved. The total effective rate of a traditional Chinese medicine treatment group is 92% which is obviously higher than that of a western medicine treatment group, and the traditional Chinese medicine is worthy of clinical popularization and application.

The invention discloses a diabetic nephropathy comprehensive diagnosis system based on artificial intelligence, and belongs to the technical field of comprehensive diagnosis. Periodically collecting blood pressure data, fundus microangiopathy data, serum creatinine data and urine protein data of a patient; acquiring blood pressure data, fundus microangiopathy data, serum creatinine data and urine protein data under the same data acquisition period; calculating a diabetic nephropathy risk index of the patient in a single data acquisition period, constructing a diabetic nephropathy risk fluctuation curve, calculating a risk trend change degree of the patient in all the data acquisition periods, predicting a diabetic nephropathy risk index of the patient in the next data acquisition period, presetting a risk index threshold value, and performing analysis and early warning. Through a data driving mode, the accuracy of diabetic nephropathy risk prediction is improved, the early warning capability is enhanced, a patient can take intervention measures as soon as possible, the disease deterioration risk is reduced, and the scientificity and the intelligent level of disease management are improved.